Boehringer-Ingelheim, a German pharmaceutical giant, has entered into a long-term strategic partnership with Austria-based CBmed GmbH Center for Biomarker Research in Medicine (CBmed). The collaboration aims to leverage translational medicine approaches to expedite the development of first-in-class oncology drugs, with the ultimate goal of transforming the lives of cancer patients and aligning with Boehringer’s ambition to cure a spectrum of cancers.
CBmed is at the forefront of translational medicine research, integrating closely with the Medical Universities of Graz and Vienna to bridge the gap between scientific discoveries and patient care. The company has established a unique multi-omics technology platform designed to accelerate the discovery of novel biomarkers. This platform integrates state-of-the-art in-house capabilities in molecular pathology, cancer immunobiology, and data science with leading scientific and medical expertise. Additionally, CBmed has access to comprehensive biobanks, including Europe’s largest biobank in Graz, which contains seven million patient samples, and BBMRI-ERIC, the world’s largest biobank network with 60 million patient samples.
This strategic partnership underscores Boehringer-Ingelheim’s commitment to advancing cancer research and developing innovative therapies that could potentially revolutionize cancer treatment.- Flcube.com
